Marine Animal Biosynthetic Constituents For Cancer Chemotherapy

Pettit, George R.; Kamano, Yoshiaki; Fujii, Youichi; Herald, Cherry L.; Inoue, Masuo; Brown, Peter de Nully; Gust, Deyens; Kitahara, K; Schmidt, Jean M.; Doubek, Dennis L.; Michel, Claude

doi:10.1021/np50016a016

Cited by 93 publications

(67 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The macrocyclic lactone bryostatin 1 is a protein kinase C (PKC) activator derived from the marine bryozoan Bugula neritina (Pettit et al, 1981). It is active against a variety of human tumor cells, including those of hematopoietic origin (Jones et al, 1990), and is currently in clinical development (Varterasian et al, 2000).…”

mentioning

confidence: 99%

Bryostatin 1 and UCN-01 Potentiate 1-β-d-Arabinofuranosylcytosine-Induced Apoptosis in Human Myeloid Leukemia Cells through Disparate Mechanisms

Wang

Grant

2003

Mol Pharmacol

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Bryostatin 1 and UCN-01 Potentiate 1-β-d-Arabinofuranosylcytosine-Induced Apoptosis in Human Myeloid Leukemia Cells through Disparate Mechanisms

Wang

Grant

2003

Mol Pharmacol

View full text Add to dashboard Cite

show abstract

“…Half-life (min), median (range) However, not until two decades ago was the antitumor potential of the dolastatin peptides discovered (31). The first dolastatin analogue to overcome synthesis and solubility challenges was cemadotin.…”

Section: Discussionmentioning

confidence: 99%

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Cunningham

Appleman

Visovatti

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of tasidotin (ILX651), a dolastatin-15 analogue, when administered on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Patients and Methods: Thirty-two patients were treated with 92 courses of tasidotin through seven dose levels determined by a modified Fibonacci scheme ranging from 3.9 to 45.7 mg/m 2 . Pharmacokinetic samples were collected during the first course. Results: Neutropenia was the principal DLT at the 45.7 mg/m 2 /d dose level. In addition, one patient also experienced grade 3 neutropenia complicated with grade 3 esophageal candidiasis and grade 3 dehydration. Only 1 of 11 patients treated at the MTD, 34.4 mg/m 2 , experienced dose-limiting neutropenia. Other common, drug-related toxicities included mild to moderate fatigue, anemia, nausea, anorexia, emesis, alopecia, and diarrhea. The best observed antitumor response consisted of stable disease and was noted in 10 patients (31%); the median duration on study for those patients with stable disease was 99.5 days compared with 37.5 days for those patients with progressive disease. Tasidotin plasma concentrations declined biphasically with an effective half-life of V55 minutes, and f11% was excreted unchanged in the urine. Conclusion: The recommended dose for phase II studies and the MTD when tasidotin is administered on days 1, 3, and 5 every 3 weeks is 34.4 mg/m 2 . The favorable toxicity profile of tasidotin compared with other antitubulin agents, including other dolastatin analogues, and its novel mechanism of action support further disease-directed evaluation of this agent.

show abstract

“…Accumulated evidences support the fact that Opisthobranchia mollusks have developed very powerful chemical defenses [44]. The earliest information about the isolation of some of these compounds was reported by Pettit in 1981 [45]. The pentapeptide Dolastatin 10 ( Fig.…”

Section: Bioactive Cyclic Peptides From Mollusksmentioning

confidence: 92%

Bioactive peptides from marine sources: pharmacological properties and isolation procedures

Aneiros¹,

Garateix²

2004

Journal of Chromatography B

292

180

View full text Add to dashboard Cite

Marine organisms represent a valuable source of new compounds. The biodiversity of the marine environment and the associated chemical diversity constitute a practically unlimited resource of new active substances in the field of the development of bioactive products. In this paper, the molecular diversity of different marine peptides is described as well as information about their biological properties and mechanisms of action is provided. Moreover, a short review about isolation procedures of selected bioactive marine peptides is offered. Novel peptides from sponges, ascidians, mollusks, sea anemones and seaweeds are presented in association with their pharmacological properties and obtainment methods.

show abstract

Marine Animal Biosynthetic Constituents For Cancer Chemotherapy

Cited by 93 publications

References 3 publications

Bryostatin 1 and UCN-01 Potentiate 1-β-d-Arabinofuranosylcytosine-Induced Apoptosis in Human Myeloid Leukemia Cells through Disparate Mechanisms

Bryostatin 1 and UCN-01 Potentiate 1-β-d-Arabinofuranosylcytosine-Induced Apoptosis in Human Myeloid Leukemia Cells through Disparate Mechanisms

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Bioactive peptides from marine sources: pharmacological properties and isolation procedures

Contact Info

Product

Resources

About